Linked Life Data

19565928

Source:http://linkedlifedata.com/resource/pubmed/id/19565928

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2009-7-1
pubmed:abstractText
Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There is an need for more efficient and less toxic treatments in this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1064-3745
pubmed:author
pubmed:issnType
Print
pubmed:volume
542
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
705-17
pubmed:dateRevised
2011-9-30
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas.
pubmed:affiliation
Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Phase I